Zoltan Takats of Imperial College, who invented the device, said he aimed to test it in such a study, involving between 1,000 and 1,500 patients with various types of cancers.
That trial process is likely to take two or three years and only then will the iKnife be submitted for regulatory approval, paving the way for its commercialization.
Takats has founded a Budapest-based company called MediMass to develop the product and he expects to strike a partnership deal with a major medical technology company to bring it to market in North America and Europe.
Hi-tech surgical equipment is being used increasingly in modern hospitals to help surgeons do a better job, most notably with the da Vinci surgical robot from Intuitive Surgical.
The current experimental version of the iKnife cost Takats and colleagues at Imperial around 200,000 pounds ($300,000) to build. Takats said the price would come down once it entered commercial production.
The research was welcomed by health minister Lord Howe, who said it could benefit both patients and the health service by reducing the number of people needing secondary operations for cancer.
The iKnife may also have a place beyond cancer, according to Takats, since it can identify tissue with an inadequate blood supply, as well as types of bacteria present in tissue. ($1 = 0.6613 British pounds)
- Link this
- Share this
- Digg this
- Email
- Reprints
0 comments:
Post a Comment